Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Jazz Pharmaceuticals Announces First Quarter 2016 Financial Results

PR Newswire May 10, 2016

Jazz Pharmaceuticals to Report 2016 First Quarter Financial Results on May 10, 2016

PR Newswire April 26, 2016

Jazz Pharmaceuticals Announces Webcast for Defitelio® (defibrotide sodium) Investor Update

PR Newswire March 30, 2016

Jazz Pharmaceuticals Announces FDA Approval of Defitelio® (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease (VOD) with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation (HSCT)

PR Newswire March 30, 2016

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

PR Newswire March 2, 2016

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results

PR Newswire February 23, 2016

Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting

PR Newswire February 18, 2016

Jazz Pharmaceuticals to Report 2015 Fourth Quarter and Full Year Financial Results on February 23, 2016

PR Newswire February 9, 2016

Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD

PR Newswire February 1, 2016

Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 11

PR Newswire January 4, 2016

Jazz Pharmaceuticals Announces Third Quarter 2015 Financial Results

PR Newswire November 9, 2015

Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

PR Newswire November 4, 2015

Jazz Pharmaceuticals to Report 2015 Third Quarter Financial Results on November 9, 2015

PR Newswire October 26, 2015

Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease

PR Newswire September 30, 2015

Jazz Pharmaceuticals Announces Second Quarter 2015 Financial Results

PR Newswire August 5, 2015

Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015

PR Newswire July 22, 2015

Jazz Pharmaceuticals to Report 2015 Second Quarter Financial Results on August 5, 2015

PR Newswire July 22, 2015

Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8

PR Newswire July 1, 2015

Aytu BioScience Acquires Commercial-Stage Prostate Cancer Biologic

PR Newswire June 9, 2015

Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or with Obstructive Sleep Apnea (OSA)

PR Newswire June 8, 2015